Revisions to Annex 1 Officially Published
The European Union publishes long-awaited changes to Annex 1.
The European Union officially released its revisions to its good manufacturing practice Annex 1 regulatory document on Aug. 25, 2022. These regulations, which pertain to manufacturing sterile drugs in the EU, are set to go into effect exactly one year after its publication, on Aug. 25, 2023.
According to the revised Annex 1: “The GMP/GDP Inspectors Working Group and the PIC/S Committee jointly recommend that the current version of annex 1, on the manufacture of sterile medicinal products, is revised to reflect changes in regulatory and manufacturing environments. The new guideline should clarify how manufacturers can take advantage of new possibilities deriving from the application of an enhanced process understanding by using innovative tools as described in the ICH Q9 and Q10 guidelines” (1).
Originally published in 2008, Annex 1 was most recently revised in 2020. Following the most recent revisions, Annex 1 sits at 59 pages; and when it was originally published it had 16.
Reference
- EU, Annex 1, vol. 4, page 1, Annex 1: Manufacture of Sterile Medicinal Products (August 2022).
Source: European Commission
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
